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Aims: Delta like 1/fetal antigen 1 (Dlk1/FA1) is a protein secreted by hormone produc-
ing cells in adult human and mice that is known to inhibit adipogenesis. Recent studies
demonstrated the role of Dlk1/FA1 in inducing insulin resistance in mice.To investigate the
involvement of circulating Dlk1/FA1 in insulin resistance and type 2 diabetes in human sub-
jects, we studied the effects of chronic FA1 on the intermediary metabolism in myotubes
established from lean, obese, and type 2 diabetic (T2D) subjects.
Methods: Myotube cultures were established from lean and obese control subjects, and
obese T2D subjects and treated with soluble FA1 for 4 days supplemented with/without
palmitate (PA). Lipid- and glucose metabolism were studied with labeled precursors while
quantitative expression of genes was analyzed using real-time PCR.
Results: Diabetic myotubes express significantly reduced insulin stimulated glucose
metabolism compared to lean myotubes and a significantly decreased basal PA oxidation.
Chronic FA1 exposure did not affect the intermediary metabolism in myotubes. Insulin
sensitivity of glucose and lipid metabolism was not affected by chronic FA1 exposure in
myotubes established from lean, obese, and T2D subjects. Instead, chronic FA1 exposure
induced pro-inflammatory cytokines expression (IL-6 and CCL2) in association with reduc-
ing adipogenic markers (ADD1, AP2, CD36, and PPARg2) in myotubes. Consistent with
this observation, addition of FA1 to cultured myotubes was show to significantly inhibit
their differentiation into adipocyte.
Conclusion: Our results exclude direct effects of FA1 on glucose and lipid metabolism in
cultured myotubes established from lean, obese, and T2D subjects. Therefore, the patho-
genesis of FA1-induced IR might mainly be mediated via the FA1-induced stimulation of
pro-inflammatory cytokines, which on turn inhibit adipogenesis in human myotubes.
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INTRODUCTION
Delta like 1/Pre-adipocyte factor-1 (Dlk1/Pref-1) is a transmem-
brane protein that contains six cysteine-rich EGF-like repeats
in its extracellular domain, similar to those found in the
Delta/Notch/Serrate family of signaling molecules (Laborda et al.,
1993; Fleming, 1998). Dlk1 is a broadly expressed protein by most
embryonic and fetal tissues in human and mice and its expression
is dramatically down-regulated to become localized only to the
hormone secreting cells in the pituitary gland, pancreatic islets,
adrenal glands, and testis (Floridon et al., 2000; Yevtodiyenko
and Schmidt, 2006). Dlk1 plays a critical role in modulating cell
fate decisions throughout development (Laborda, 2000) and has
Abbreviation: FFA, free fatty acids.
been identified as a negative regulator of adipocyte differentiation
(Smas and Sul, 1993). Mice deficient in Dlk1 displayed growth
retardation, obesity, skeletal malformations, and abnormalities of
hematopoiesis (Moon et al., 2002; Sakajiri et al., 2005). Also, in
the human syndrome of maternal uniparental disomy (UPD)14
(where Dlk1 is silent), patients exhibit obesity, hypotonia, pre-
mature puberty, macrocephaly, short stature, and small hands
(Berends et al., 1999).
The extracellular domain of the Dlk1 is proteolitically cleaved
by tumor necrosis factor alpha converting enzyme (TACE) (Wang
and Sul, 2006) and shed into the circulation as a soluble active
form named fetal antigen 1 (FA1) (Jensen et al., 1994). Therefore,
Dlk1/FA1 can function in a paracrine/endocrine fashion (Jensen
et al., 1993). Circulating Dlk1/FA1 is present at very high levels in
serum/amniotic fluid of pregnant human and mice (Bachmann
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et al., 1996; Jensen et al., 1997). In addition, the serum level of FA1
is elevated in some human pathological conditions including neu-
rofibromatosis (Jensen et al., 1999), renal failure (10 times higher)
(Jensen et al., 1997), and small cell lung cancer patients (10–1000
times higher) (Harken et al., 1999).
Consistent with to its role in adipogenesis, we have shown that
systemic administration of FA1 in adult mice led to reduce both
fat and bone mass in a dose-dependent manner (Abdallah et al.,
2007b).
Recently, transgenic mice with high circulating level of FA1 were
shown to display a lipodystrophic phenotype in association with
increased whole body insulin resistance suggesting an endocrine
function for FA1 in insulin resistance and T2D (Villena et al.,
2008).
In our attempt to investigate the potential role of FA1 in insulin
sensitivity and T2D of human subjects, we studied the chronic
effect of dlk1/FA1 on insulin sensitivity, and lipid metabolism in
myotube cultures established from lean, obese, and type 2 diabetic
(T2D) (Gaster et al., 2002) subjects. Our detailed biochemical and
molecular analysis revealed an immune-modulatory effect of FA1
on increasing the production of pro-inflammatory cytokines in
cultured myotubes without affecting their insulin sensitivity.
MATERIALS AND METHODS
MATERIALS
Dulbecco’s modified Eagle’s medium, fetal calf serum (FCS),
penicillin-streptomycin-amphotericin B, and trypsin-EDTA were
obtained from Invitrogen (Invitrogen, Scotland, UK). Ultroser
G was purchased from Pall Biosepra (Cergy-Saint-Christophe,
France). Protein assay kit was purchased from Bio-Rad (Copen-
hagen, Denmark). Palmitic acid, l-carnitine, and ECM-gel were
purchased from Sigma Chemical Co. (St. Louis, MO, USA). Bovine
serum albumin (BSA; essentially fatty acid free) was from Cal-
biochem (VWR, Roskilde, Denmark). Insulin Actrapid was from
Novo Nordisk (Bagsvaerd, Denmark).
FETAL ANTIGEN 1
The full soluble ectodomain, active form of Dlk1 protein named
FA1, was purified by immuno-specific affinity chromatography
from human amniotic fluid and kindly provided by Dr. Bøger Teis-
ner (Immunology Dept., OUH, Denmark) as described previously
(Jensen et al., 1993).
HUMAN STUDY SUBJECTS
Eight lean, eight obese control subjects, and eight obese T2D
patients participated in the study (Table 1), and their clinical
characteristics have previously been published (Ortenblad et al.,
2005; Gaster and Beck-Nielsen, 2006). All subjects gave writ-
ten, informed consent, and the study was approved by the local
ethics committee of Funen and Vejle County. Muscle biopsies were
obtained from the vastus lateralis muscle by needle biopsy under
local anesthesia. Diabetic patients were treated with either diet
alone or in combination with sulfonylurea, metformin, or insulin
withdrawn 1 week before the study. The patients suffered from no
diabetic complications except for simplex retinopathy. The con-
trol subjects had normal glucose tolerance and no family history
of diabetes.
Table 1 | Clinical characteristics of the study subject.
Control,
lean
Control,
obese
T2D
n 8 8 8
Age (years) 51±1 49±1 50±2
Weight (kg) 71.5±3.7 109.3±7.6* 106.6±3.6*
BMI (kg/m2) 24.3±0.6 34.4±1.9* 34.5±1.0*
Fasting plasma glucose (mM) 5.7±0.1 5.9±0.1 9.6±0.7#
Fasting serum insulin (pM) 26.6±6.8 53.6±5.9* 102.5±10.4#
Glucose infusion rate
(mg/min)
375.3±20.4 232.9±21.9.3* 124.3±17.8#
HbA1c (%) 5.6±0.1 5.5±0.1 7.6±0.6#
Fasting total cholesterol (mM) 5.25±0.28 5.48±0.57 5.31±0.39
Fasting LDL cholesterol (mM) 2.90±0.26 3.39±0.45 3.18±0.33
Fasting HDL cholesterol (mM) 1.82±0.17 1.44±0.20 1.36±0.03*
Fasting plasma triglyceride
(mM)
1.19±0.19 1.41±0.21 1.73±0.31
Data are means±SE. *Significant different from the lean controls (P<0.05),
#significant different from the lean and obese controls (P<0.05).
CELL CULTURE
Cell cultures were established as previously described (Gaster
et al., 2001a,b,c). In brief, muscle tissue was minced, washed,
and dissociated for 60 min in 0.05% trypsin-EDTA. The cells
obtained were seeded for up-scaling on ECM-gel coated dishes
after 30 min of pre-plating. Growth medium contains DMEM
supplemented with 2% FCS, 2% Ultroser G, 50 U/ml penicillin,
50µg/ml streptomycin, and 1.25µg/ml amphotericin B. Cells
were sub-cultured twice before final seeding. At 75% conflu-
ence, the growth medium was replaced by basal medium (DMEM
supplemented with 2% FCS, 50 U/ml penicillin, 50µg/ml strep-
tomycin, 1.25µg/ml amphotericin B, and 25 pmol/l insulin) in
order to induce differentiation. The cells were cultured in humid-
ified 5% 2CO2 atmosphere at 37˚C, and medium was changed
every 2–3 days.
EXPERIMENTAL DESIGN
Human myotubes established from lean, obese, and T2D subjects
were allowed to differentiate under physiological conditions of
insulin (25 pmol/l) and glucose (5.5 mmol/l). All myotube cul-
tures were used for analysis day eight after onset of differentiation.
Myotubes were exposed to three different protocols: (1) the last
4 days myotubes established from all three groups were exposed
with/without 3.0µg/ml FA1 followed by subsequent determina-
tion of glucose uptake, oxidation and storage, lipid uptake, and
oxidation at baseline and during acute insulin stimulation and
protein content. RNA were isolated from sister cultures. (2) The
last 4 days myotubes established from lean subjects were exposed
with/without 3.0µg/ml FA1 supplemented with 0.4 mmol/l PA
followed by subsequent determination of glucose uptake, oxi-
dation and storage, lipid uptake, and oxidation at baseline and
during acute insulin stimulation and protein content. RNA were
isolated from sister cultures. (3) lean myotubes were exposed for
0.4 mmol/l PA with/without 3.0µg/ml FA1 day 4 and PA incor-
poration into the myotubes at various time points determined
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by scintillation proximity assay (SPA) method (Gaster, 2009b) for
7 days (168 h). PA: BSA molar ratio was 2.5:1.
SUBSTRATE OXIDATION
Glucose and palmitate (PA) oxidation was determined by a 96
multi-well tracer technique as previous described (Gaster, 2009a).
Substrate oxidation was monitored by incubating myotubes with
[1-14C]-PA (2.0µCi/ml) in a final concentration of 0.4 mmol/l
PA and [14C(U)]-glucose (2.0µCi/ml) in a final concentra-
tion of 5.0 mmol/l glucose with subsequent capture of liberated
14CO2 for 4 h at 37˚. Trapped radioactivity was determined on a
Microbeta counter (PerkinElmer, Finland).
ADIPOCYTE DIFFERENTIATION
AIM Cells were seeded at 3× 104 cells/cm2 in 60 cm2 petri-dishes
(for RNA isolation) or in six-well plates (for histochemical stain-
ing and flow cytometry studies) and cultured in a standard growth
medium. At 90–100% cell confluence, the medium was replaced
by high-glucose Dulbecco’s modified MEM (DMEM; Gibco Invit-
rogen) containing 10% FCS and supplemented with adipogenic-
induction mixture (AIM) [containing 10−7 M dexamethasone
(dex), 0.45 mM isobutyl methyl xanthine (IBMX), 2× 10−6 M
insulin (all from, Sigma-Aldrich, Vallensbaek strand, Denmark),
and 1µM Rosiglitazone [(BRL49653; Novo Nordisk, Bagsvaerd,
Denmark)]. The adipogenic medium was replaced every 3 days.
Cells differentiated into adipocytes were washed twice in PBS and
lipid staining was performed using Oil Red O stain.
GLUCOSE AND LIPID UPTAKE
Glucose uptake was measured by capturing 2-[1-14C]-deoxy-
glucose and lipid uptake was measured as the incorporation of
[1-14C]-PA (2.0µCi/ml) as previously described (Gaster and
Beck-Nielsen, 2004, 2006). Radioactivity was determined on a
Microbeta counter (PerkinElmer, Finland).
GLYCOGEN SYNTHESIS
Glycogen synthesis was measured as previous described (Gaster
and Beck-Nielsen, 2004) in 96 well plates. Radioactivity was
measured with a Microbeta counter (PerkinElmer, Finland).
PA INCORPORATION IN INTRACELLULAR LIPIDS
Incorporation of PA over time into human myotubes was esti-
mated by an SPA (Gaster, 2009b) taking the advantage of the
fact that the accumulated radioactivity provides signal stronger
than the signal coming from the media. Differentiated myotubes
were exposed to increasing C-14 labeled PA concentrations
(0.4 mmol/l) with/without 3.0µg/ml FA1 for 7 days. PA incor-
porated into the myotubes was monitored regularly by measuring
accumulation of radioactivity (Microbeta, PerkinElmer, Finland).
RNA ISOLATION AND REAL-TIME
Total RNA was isolated from human myotubes using a single
step method with TRIzol (Invitrogen A/S, Tastrup, Denmark)
according to the manufacturer’s instructions. The integrity and
purity of total RNA was verified spectrophotometrically and by
gel-electrophoresis on 0.8% SeaKem agarose (BMA, Hellerup,
Denmark). cDNA was synthesized from 5µg of total RNA using
Table 2 | Primer sequences used for real-time PCR gene expression
analysis.
Gene Primer sequence Product
size (bp)
REFERENCE GENES
β-Actin 5′-TGTGCCCATCTACGAGGGGTATGC-3′ F 433
5′-GGTACATGGTGGTGCCGCCAGACA-3′ R
CYTOKINE GENES
Dlk1 5′-CTGGACGGTGGCCTCTATGAATG-3′ F 130
5′-ATCATCCACGCAGGTGCCTC-3′ R
IL-1b 5′-AGGAAGATGCTGGTTCCCTGC-3′ F 126
5′-CAGTTCAGTGATCGTACAGGTGC-3′ R
IL-6 5′-CCACACAGACAGCCACTCACCTC-3′ F 276
5′-CTGGCTTGTTCCTCACTACTCTC-3′ R
CC3 5′-CCTGCTACTAACCCACCTCC-3′ F 139
5′-AACAGTGACTGGAACATCCCC-3′ R
CD36 5′-AGTCACTGCGACATGATTAATGGT-3′ F 74
5′-CTGCAATACCTGGCTTTTCTCAA-3′ R
GLUT1 5′-GGCCAAGAGTGTGCTAAAGAA-3′ F 201
5′-ACAGCGTTGATGCCAGACAG-3′ R
GLUT4 5′-TGGGCGGCATGATTTCCTC-3′ F 88
5′-GCCAGGACATTGTTGACCAG-3′ R
TNFa 5′-TTCTCGAACCCCGAGTGACAAG-3′ F 375
5′-CCCTTCTCCAGCTGGAAGACC-3′ R
CCL2/MCP-1 5′-CCAATTCTCAAACTGAAGCTCGCAC-3′ F 372
5′-GTTAGCTGCAGATTCTTGGGTTGTG-3′ R
CPT-1a 5′-TGCTTTACAGGCGCAAACTG-3′ F 338
5′-TGGAATCGTGGATCCCAAA-3′ R
LXRa 5′-GAGGGCTGCAAGGGATTCTT-3′ F 330
5′-GTTACACTGTTGCTGGGCAG-3′ R
LXRb 5′-GGCGAGGGTGTCCAGCTAA-3′ F 90
5′-CGGAGAAGGAGCGTTTGTTG-3′ R
ADIPOCYTE MARKERS
FASN 5′-CTCCGAAGGGCACGAACAC-3′ FR 290
5′-TAGAGGGAGCCAGAGAGACG-3′
APM1 5′-TGTTGCTGGGAGCTGTTCTACTG-3′ FR 234
5′-ATGTCTCCCTTAGGACCAATAAG-3′
aP2 5′-GCCAGGAATTTGACGAAG TC-3′ FR 220
5′-TGGTTGATTTTCCATCCC AT-3′
ADD1 5′-GGAGCCATGGATTGCACTTTC-3′ FR 261
5′-ATCTTCAATGGAGTGGGTGCAG-3′
a commercial revertAid H minus first strand cDNA synthesis kit
(Fermentas, Copenhagen, Denmark) according to manual instruc-
tions. Real-time PCR (RT)-PCR was performed in iCycler IQ
detection system (Bio-Rad, Herlev, Denmark) by using SYBR®
Green I as a double-strand DNA-specific binding dye. Thermo-
cycling was performed in a final volume of 20µl containing
3µl of cDNA sample (diluted 1:20), 20 pmole of each primer,
and 2× iQ™ SYBR® Green Supermix (Bio-Rad). The quantifi-
cation of each target gene and β-actin mRNA using primers in
Table 2 was performed in separate tubes. Gene expression lev-
els for each target gene were calculated using the comparative Ct
method [(1/(2∆Ct) formula, where∆Ct is the difference between
Ct target and Ct-reference] after normalization to β-actin mRNA
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(PerkinElmer’s User Bulletin No. 2). Data were analyzed using
optical system software version 3.1 (Bio-Rad) and Microsoft Excel
2000 to generate relative expression values (Frederiksen et al.,
2008).
STATISTICAL ANALYSIS
The data in the text, tables, and figures are presented as mean± SE.
The statistical analyses were performed with INSTAT 2.01 (Graph-
Pad, USA). P ≤ 0.05 was considered to be significant.
RESULTS
CHRONIC FA1 EXPOSURE DID NOT AFFECT THE INTERMEDIARY
METABOLISM OF LEAN MYOTUBES
Increasing serum levels of FA1 was shown to be associated
with impairment of insulin sensitivity (Villena et al., 2008).
In order to investigate the direct involvement of FA1 in stim-
ulating insulin resistance in myotubes, we studied the effect
of soluble FA1 on different parameters of insulin sensitiv-
ity in cultured myotubes established from lean subjects. As
shown in Table 3, lean myotubes exposed to chronic (4 days;
3.0µg/ml) FA1 did not express significantly different rates of
neither glucose and lipid uptake nor glucose oxidation and glyco-
gen synthesis rates as compared to non-treated control cultures
(Table 3).
Table 3 | Metabolic characteristics of lean myotubes (n=8)
with/without exposure to FA1 (3µg/ml) for 4 days.
Metabolic characteristics −FA1 +FA1 (3µg/ml)
GLUCOSETRANSPORT (nmol/min/mg)
Baseline 0.715 (±0.055) 0.680 (±0.062)
Acute insulin stimulation 0.873 (±0.087)* 0.981 (±0.132)*
Insulin effect (ratio) 1.205 (±0.055) 1.424 (±0.099)
GLYCOGEN SYNTHESIS (nmol/min/mg)
Baseline 0.213 (±0.069) 0.217 (±0.035)
Acute insulin stimulation 0.390 (±0.040)* 0.380 (±0.054)*
Insulin effect (ratio) 1.856 (±0.120) 1.811 (±0.131)
GLUCOSE OXIDATION (nmol/min/mg)
Baseline 0.106 (±0.011) 0.099 (±0.014)
Acute insulin stimulation 0.128 (±0.012)* 0.137 (±0.015)*
Insulin effect (ratio) 1.221 (±0.083) 1.370 (±0.201)
LIPID UPTAKE (nmol/min/mg)
Baseline 1.490 (±0.078) 1.420 (±0.089)
Acute insulin stimulation 2.040 (±0.090)** 1.940 (±0.099)**
Insulin effect (ratio) 1.358 (±0.045) 1.354 (±0.050)
LIPID OXIDATION (pmol/min/mg)
Baseline 39.94 (±2.52) 36.66 (±2.78)
Acute insulin stimulation 40.14 (±2.77) 36.83 (±2.77)
Insulin effect (ratio) 1.000 (±0.03) 0.975 (±0.04)
Data represents mean±SEM. P<0.05 is considered significant. Baseline condi-
tions refer to an insulin concentration of 25 pmol/l and acute insulin stimulation
refers to an insulin concentration of 1µmol/l.
*P<0.05, baseline vs. acute insulin stimulation.
**P<0.001, baseline vs. acute insulin stimulation.
CHRONIC FA1 TREATMENT DOES NOT REDUCE THE INSULIN
SENSITIVITY OF THE GLUCOSE AND LIPID METABOLISMS IN
MYOTUBES ESTABLISHED FROM LEAN, OBESE, AND T2D SUBJECTS
We also investigated the direct effect of FA1 on insulin and lipid
metabolisms in both obese and T2D myotubes. As shown in
Figure 1, treatment of obese and diabetic cultured myotubes for
4 days with purified hFA1 did not significantly reduce any of the
insulin sensitivity parameters including glucose uptake and oxi-
dation, glycogen synthesis, PA uptake, and oxidation as compared
to non-treated control cultures (Figure 1).
CHRONIC FA1 EXPOSURE INDUCES PRO-INFLAMMATORY GENE
EXPRESSION IN HUMANMYOTUBES AND INHIBITS ADIPOGENIC
MARKERS
We further studied the effect of FA1 treatment on gene expression
profile of inflammatory, adipogenic, and glucose transport genes
in cultured myotube established from lean, obese, and T2D sub-
jects (Figure 2). As shown in Figure 2, FA1 treatment for 4 days
significantly reduce the mRNA expression of adipogenic differen-
tiation markers ADD1, AP2, CD36, and PPARΥ2 in association
with increasing the expression of the pro-inflammatory markers
IL-6 and CCL2 (Figure 2). Consistent with our biochemical assays,
FA1 treatment did not change the mRNA expression of GLUT1 and
GLUT4 that are important for basal and insulin stimulated glucose
uptake respectively.
FA1 INHIBITS ADIPOCYTE DIFFERENTIATION OF HUMANMYOTUBES
Delta like 1/FA1 has been established as an inhibitor of adipocyte
differentiation and fat mass in vitro and in vivo (Abdallah
et al., 2004, 2011b). Thus, we studied the inhibitory effect
of FA1 on adipogenic differentiation of myotubes as a con-
sequence of FA1-induced down-regulation of the above indi-
cated adipogenic markers. As shown in Figure 3, the addi-
tion of soluble FA1 to the myotube cultures inhibited their
adipocyte differentiation as assessed by significant reduction in
Oil red O staining for fatty acid accumulation (Figure 3A) and
marked down-regulation of the expression of adipogenic mark-
ers PPARg2, LPL, and aP2 (Figure 3B). These data showed
that Dlk1/FA1 exerts an anti-adipogenic effect on human
myotubes.
FA1 DID NOT CHANGE THE EFFECT OF PA ON THE INTERMEDIARY
METABOLISM
In order to clarify whether the inhibitory effect of FA1 on adi-
pogenesis in myotubes could improve their sensitivity for PA-
induced insulin resistance, we treated the established cultured
myotubes from lean subjects with PA in the presence or the
absence of FA1 for 4 days. The incubation of lean myotubes
with PA with/without FA1 for 4 days did not show any sig-
nificant changes in insulin sensitivity parameters for glucose
uptake, oxidation, glycogen synthesis, PA uptake, and oxidation
(Figure 4).
CHRONIC FA1 DID NOT REDUCE/IMPAIR THE INCORPORATION OF PA
INTO TAG IN HUMANMYOTUBES
The incorporation and accumulation of fatty acid in lean
myotubes were studied by SPA methodology allowing us to
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FIGURE 1 | Effect of FA1 treatment on the insulin sensitivity of cultured
myotubes from lean, obese, andT2D subjects. Human myotubes
established from lean, obese, and T2D subjects were differentiated for 4 days
under physiological conditions and subsequently treated without (control) or
with 3.0µg/ml FA1 for further 4 days, as described in Section “Materials and
Methods.” Glucose uptake (GT), glucose oxidation (Gox), glycogen synthesis
(GS), lipid uptake (PAup), and lipid oxidation (Lox) were determined at baseline
and during acute insulin stimulation. Data represented as ratio of (insulin
stimulation/basal) with/without FA1. Data are shown as mean±SEM. N =8 in
each group.
FIGURE 2 | Effect of FA1 treatment on gene expression of metabolic,
pro-inflammatory, and adipogenic markers in cultured myotubes
from lean, obese, andT2D subjects. Cells were differentiated for 4 days
under physiological conditions and subsequently treated without
(control) or with 3.0µg/ml FA1 for further 4 days, as described in Section
“Materials and Methods.” Gene expression analysis was measured by
real-time PCR and the expression analysis of each target gene was
represented as relative expression to β-actin. Data from the three groups
were pooled as there were no differences between their expression
levels of several genes important for various aspects of the intermediary
metabolism. Data represented as mean±SEM (N =8 per each group);
*P < 0.05.
measure the continuous PA incorporation into myotubes at
0.4 mmol/l PA with or without FA1 for 7 days. The accu-
mulation of PA was independent of the presence of FA1
(Figure 5).
DISCUSSION
We have studied the in vitro effect of circulating FA1 on the insulin
sensitivity of human myotubes established from lean, obese, and
T2D subjects. Our metabolic studies clearly showed that FA1 does
www.frontiersin.org April 2013 | Volume 4 | Article 45 | 5
Abdallah et al. FA1 in cultured human myotubes
FIGURE 3 | Effect of FA1 on adipocyte differentiation of myotubes.
(A) Soluble active form of Dlk1 (FA1) inhibits the adipocyte
differentiation of myotubes. Cultured myotubes established from lean
subjects were induced to differentiate into adipocyte without (control)
or with 3µg/ml of purified FA1. Adipocytes were stained at day 12 with
Oil red O and quantified by microscopic investigation. (B) Expression of
adipogenic markers during the time course of differentiation in the
absence and the presence of FA1. Gene expression analysis was
quantified by real-time PCR and the expression of each target gene
was represented as relative expression to β-actin. Data are shown as
mean±SEM of at least three independent experiments; *P <0.05 and
**P <0.005.
FIGURE 4 | Effect of FA1 on insulin sensitivity of cultured myotubes
exposed to PA. Cultured myotubes established from lean subjects were
differentiated for 4 days under physiological conditions and subsequently
exposed to 0.4 mmol/l PA with or without 3.0µg/ml FA1 for further
4 days, as described in Section “Materials and Methods.” Glucose
uptake (GT), glucose oxidation (Gox), glycogen synthesis (GS), lipid
uptake (PAup), and lipid oxidation (Lox) were determined at baseline and
during acute insulin stimulation. Data represented as ratio of (insulin
stimulation/basal) with/without FA1. Data are shown as mean±SEM.
N =8.
not exert a direct effect on insulin sensitivity of glucose and lipid
metabolism in myotubes. Instead, chronic exposure of FA1 stimu-
lates the production of pro-inflammatory cytokines by myotubes
in association with inhibiting their adipogenic markers.
Cultured human myotubes are the most similar cell system
to intact skeletal muscle that can be modulated ex vivo. Com-
pared to rodent models, our cultured myotubes expresses the
right genetic background as well as the specific skeletal mus-
cle phenotype. The extracellular environment can be controlled
precisely and kept relatively constant over time, without interfer-
ence from systemic homeostatic compensatory mechanisms. We
and others have reported several potential intrinsic deficiencies
in myotubes from individuals with T2D, i.e., reduced capacity
for complete oxidation of labeled PA to CO2 compared to con-
trol myotubes or reduced insulin mediated increase in glycogen
synthesis, and these dysfunctions was reproduced in our present
study (Gaster and Beck-Nielsen, 2004; Gaster et al., 2004; Gaster,
2009a).
We and others have shown that the increased serum lev-
els of FA1 was associated with human pathological conditions
including neurofibromatosis (5 times higher than the normal
range) (Jensen et al., 1999), renal failure (10 times higher)
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FIGURE 5 | Accumulation of PA in myotubes induced with/without FA1.
Cultured myotubes from lean subjects were exposed to 0.4 mmol/l PA
with/without 3.0µg/ml FA1 for 7 days and the intracellular accumulation of PA
was regularly monitored. The figure illustrates the time course of PA
incorporation into myotubes in the presence () and the absence (N) of FA1.
Data are shown as mean±SEM. N =6.
(Jensen et al., 1997), small cell lung cancer patients (10–1000
times higher) (Harken et al., 1999), and estrogen deficiency-
induced osteoporosis in post-menopausal women (Abdallah et al.,
2011a).
With regard to IR, increasing serum levels of FA1 in mice
was shown to be associated with IR through an indirect mech-
anism involving lipodystrophy-induced IR in peripheral fat
(Villena et al., 2008). In accordance, our finding that both
insulin sensitivity and lipid metabolism were not per se affected
by chronic FA1 exposure in human myotubes suggests that
myotube is not the primary targeted tissue by FA1-induced
IR.
Our data showed that Dlk1/FA1 inhibits the adipocyte differ-
entiation of cultured human myotubes via a mechanism involved
the down-regulation of the adipogenic regulatory genes. This
finding is consistent with the established inhibitory effect of
Dlk1/FA1 on the adipocyte differentiation of 3T3-L1 and mes-
enchymal stem cells as well as on reducing fat mass in vivo
where, the increased serum levels of FA1 showed to be neg-
atively correlated with fat mass in mice (Lee et al., 2003;
Abdallah et al., 2007b). Moreover, in other species includ-
ing sheep and pigs, the high circulating level of FA1 due
to genetic mutation of dlk1 region was shown to be associ-
ated with reducing fat mass (Freking et al., 2002; Kim et al.,
2004).
Several studies suggested a strong link between inflamma-
tion and the development of insulin resistance. Activation of
inflammatory pathways in fat and skeletal muscles showed to
induce local and systemic insulin resistance (Cai et al., 2005;
Plomgaard et al., 2005; Bastard et al., 2006). In this study,
the stimulatory effect of Dlk1/FA1 on increasing the produc-
tion of IL-6 and monocyte chemotactic protein (MCP)-1 by
myotubes did not seem to be involved in pathogenesis of insulin
resistance in T2D patients (Kalupahana et al., 2012) due to
the fact that we could not detect any differences in the FA1-
induced pro-inflammatory cytokines in myotubes between T2D
and lean and obese controls. Thus, our data could not identify
a link between the FA1-induced inflammation in myotubes and
insulin resistance. On the other hand, we have recently identified
the Dlk1/FA1-induced inflammation as a potential mechanism
that mediates the inhibitory effect of Dlk1/FA1 on osteoblast
and adipocyte differentiation of human mesenchymal stem cells
(Abdallah et al., 2007a) as well as its stimulatory effect on osteo-
clast differentiation from hematopoietic stem cells in bone mar-
row (Abdallah et al., 2011b). Thus, it is plausible that the anti-
adipogenic effect of Dlk1/FA1 on myotubes is mediated though
a mechanism involved increasing the production of cytokines by
Dlk1/FA1.
The association between Dlk1/FA1 expression and inflam-
mation has also been demonstrated in a recent report that
demonstrated the stimulatory effect of Dlk1/FA1 protein on
pro-inflammatory cytokines by immune and fat cells (Chacon
et al., 2008). Furthermore, several studies support the involve-
ment of Dlk1/FA1 in general biological processes associated
with stimulating inflammatory responses including detection
of high Dlk1/FA1 expression levels during ear wound heal-
ing (Samulewicz et al., 2002), during liver regeneration in liver
injured mice (Jensen et al., 2004), and by satellite cells dur-
ing muscle regeneration (Crameri et al., 2004). In conclusion,
FA1 per se seems to not induce insulin resistance or worsen
pre-existing insulin resistance in human myotubes, but shows
its effect at the gene level by down-regulating the expres-
sion of adipogenic differentiation markers and up-regulating
pro-inflammatory cytokines.
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